SureTrader SureTrader
Home > Boards > US OTC > Medical - Equipment >

GeneSYS ID Inc. (GNID)

GNID RSS Feed
Add GNID Price Alert      Hide Sticky   Hide Intro
Moderator: The_Free_Nebula, waterchaser, Bruce the Stock Guy, Toxic Avenger, Peggy, rschwa
Search This Board:
Last Post: 9/27/2016 9:18:01 PM - Followers: 121 - Board type: Free - Posts Today: 336
 


Rx Safes

RX Safes Inc.
 

http://www.rxdrugsafe.com


EXECUTIVE SUMMARY

http://www.rxdrugsafe.com/files/Executive%20Summary_RX%20Safes_December%202015.compressed.pdf

INVESTORS SUMMARY

http://www.rxdrugsafe.com/files/Rx%20Safes%20Presentation%20December%202015_Website%20Version.compressed.pdf

RESEARCH REPORT

http://rxdrugsafe.com/files/Rx%20Safes%20Inc%20-%20Research%20Initiation.pdf



 

Rx Safes, Inc. was incorporated in 2010 in the State of Nevada. Our founders have an extensive background designing and developing consumer and commercially based fingerprint security products including garage door openers, front door locks, thermostats and mail boxes for companies such as Master Lock Corporation, Honeywell and The Overhead Door Company and developing marketing and sales programs through multiple distribution channels, including The Home Depot, Costco and Sears. The founders saw an opportunity to apply their knowledge with the commercialization of this technology to provide solutions for healthcare applications with an initial focus on drug security.

 

We are a technology and product development company that works with our contract manufacturer to design, develop and manufacture innovative patented, embedded fingerprint technology solutions for medication security and adherence, aimed at fulfilling consumer and institutional healthcare safety. We offer our proprietary fingerprint interface as a solution for customers to license and integrate into their own products, we jointly develop products with OEM partners to deliver enhanced security, accountability and convenience to their existing product offerings, and we use our technology to develop our own fingerprint based drug security products and solutions. All of our current and future products and fingerprint technology is protected under US Patent No. 6,766,040
 

Our product roadmap incorporates comprehensive solutions to address all aspects of drug security including:

 

§    Secure medication lockboxes for use in home and healthcare facilities;

§    Secure medication management and monitoring products;

§    Secure mobile medical stations to administer in home care;

§    Drug drop-boxes to dispose unused medication; and

§    Rx Safes’ secured OEM products – medicine carts, PCA, access control and storage.
 

                                           
 CEO Message

https://www.youtube.com/watch?v=nbIcatcZlqQ 





 
Share Structure as of March 29, 2016
 
Shares Outstanding: 11,633,243
 
*******Float 370,225******* 
 

Our mission is as simple as it is powerful – to become the leading provider of autonomous fingerprint medical security solutions for the professional healthcare and consumer markets!

As fingerprint security experts, we are taking a comprehensive approach to drug security providing a variety of secure fingerprint products and solutions for both the professional and consumer healthcare markets. Our team has over 30 years of experience in designing and manufacturing fingerprint security products and have been innovators in the development and commercialization of embedded fingerprint consumer products. The Rx Safes, Inc. founders have been pioneers in the fingerprint recognition space for more than 20 years. The company CEO, Lorraine Yarde, negotiated and executed the single largest wholesale order of a biometric consumer product to The Home Depot, bringing more than $14M in revenue on that single order. Our team has a successful track record in developing products for consumers and corporations, utilizing cutting edge fingerprint technology, incorporating functional design, ease of use, extended battery life and security appeal in a high tech package.

Collectively we have sold more than 20,000 fingerprint safes and 40,000 garage door openers to leading merchants such as The Home Depot, The Sharper Image, COSTCO, Lowes, SEARS, as well as licensed technology to dozens of chip manufacturers such as OKI and Fujitsu. In 2010, the founders saw a special need in healthcare where our patented technology could be effectively utilized to not only secure prescription medications, but to also prevent drug diversion, both at home and in professional healthcare facilities. Since that time, we have committed to constantly improve both our technology and products, to offer and deliver the easiest to use and most secure method of securing the storage and administration of drugs at home, in hospitals, emergency medical clinics, assisted living facilities, outpatient and recovery centers, sober houses and ambulance vehicles.

More than $15 Billion dollars are lost annually in healthcare due to drug abuse, drug diversion and insurance claims based on theft and fraud. Drug Diversion happens when medications are left in unsecure environments, where there is no real control or accountability.


 
 



White House Drug Policy Office Announces $86 Million to Prevent Youth Substance Use in Almost 700 Communities | whitehouse.gov




Our flagship product, the Rx DrugSAFE Fingerprint Medication Lockbox, is an example of the integration of our patented fingerprint technology into one our own product offerings. The Rx DrugSAFE demonstrates how our fingerprint technology makes a product smarter and more secure to prevent accidental poisonings, drug theft and diversion within the home. The same technology is being applied within commercial healthcare environments, to offer facilities a secure and convenient means by which to control and monitor access to medications, addressing loss prevention and providing tighter security and controls overall for variety of healthcare applications, in turn lowering facility costs and reducing liability.


Our current patented fingerprint technology offers a simple fingerprint interface, allowing the registration and/or deletion of multiple users. Our current design employs methods that incorporate low power consumption offering extended battery life. We have recently taken steps to enhance our fingerprint interface and our current units under production offer a new, additional layer of security, by introducing an administrative function. This allows a homeowner, or a healthcare manager, to manage the enrollment of additional users who should have either permanent or temporary access to the safes contents.


As our technology continues to evolve, we are constantly re-evaluating options for redesign of the core electronics and mechanical locking mechanisms used in our products in order to provide further security and convenience for our customers as well as to introduce new functionality. We are taking our experience in security product design and fingerprint technology and our understanding of customer’s wants and needs and are developing a product line which we believe will help address both the social and economic issues caused by prescription drug abuse, misuse and diversion both in the home and within commercial healthcare environments. We are now in the process of incorporating new technology features to work in conjunction with our fingerprint interface, which will allow our products and technology to become “smarter” and provide additional benefits to end users, providing feedback and functionality through interactive applications that will run on smart devices and computers.


Our ultimate goal for our consumer focused products is to make it widely attainable to the public through medical reimbursement. To this end, we are continuing to pursue FDA registration, set aside funds to pay the necessary product and facility registration and have also begun the process of navigating CMS and private health insurance companies to recognize the product as a medical device and offer reimbursement of the majority of the purchase price through their plans so that their members will only have to pay a small co-payment to purchase the product.
 

Over the course of the next 12 months, we intend to incorporate the following additional technology and functionality into our patented biometric interface:

 

§    The introduction new touch and swipe sensor options to suit the needs of a variety of consumer and commercial healthcare products and applications.

§    Bluetooth technology offering interoperability with multiple healthcare related applications on smart devices,

§    WIFI capability with cloud based integration, providing two-way communication between our technology/products and remote applications.

§    Improved audible feedback.

§    Medication adherence features.

§    Expanded administration to support commercial healthcare compliance.

§    GPS tracking capabilities to provide location-based information on portable healthcare security products using our technology interface.


 

Our product development plan over the next 24 months includes a variety of new products incorporating our proprietary fingerprint interface including:

 

§    Fingerprint controlled dosing device;

§    Portable HIPAA compliant fingerprint EH;

§    Fingerprint OEM module;

§    Finperprint Tele-Medicine solution;

§    Biometric physical and electronic health records; and

§    Custom fingerprint technology solutions


Our consumer products target at risk users and stakeholders who understand the importance of medication security in the home. There are no other medication storage devices as secure and easy to use as the Rx DrugSAFE to address the needs of this market. There are a handful of low cost, low-grade, plastic lock box options that utilize unsecure, mechanical locking mechanism. Examples of these are from companies such as Lockmed and Saferlock. In our testing of these company’s products, 12 year olds were able to easily thwart their locking mechanisms and then re-secure the products in their apparent “locked” state, meaning that an unsuspecting parent would not be aware that these products had been accessed by their child. These products may be inexpensive but they offer users a false sense of security and minimum security and we do not consider these competitors as a real threat.

 




Consumer Products

 

RX Safes Consumer Products Can Be Found At:


Image result for walgreens gif

Image result for CVS Health  gif

Our embedded fingerprint products and technology also offer a low cost alternative for healthcare facilities looking to enhance overall drug security and provide tighter controls and compliance without the need to the implement costly, enterprise-wide biometric systems. Decentralized medication management systems from companies such as Pyxis involve complex integration with Pyxis back end systems, require extensive facility resources and are costly to implement, with basic installation costing several hundred thousand dollars. These implementations completely change the way a facility conducts its business, requiring constant maintenance and costly personnel training. In comparison, the implementation of Rx Safes’ fingerprint embedded technology interface integrates seamlessly into a facility’s existing systems and medication dispensing equipment. We are not aware of any other companies looking to market embedded biometric solutions into healthcare. If in the future we identify companies looking to enter this marketplace, our patent protection will provide a barrier to entry and may result in additional opportunity for the company in the form of a collaborative development or licensing of our patent rights to such third party companies.


The RxDrugSAFE PRO has been designed to accommodate a greater number of prescription pill bottles of various sizes to support the needs of a variety of healthcare environments including assisted living facilities, nursing homes and emergency service vehicles. The Rx DrugSAFE IC, which is being designed to be securely mounted inside of an existing medicine cabinet. The RxDrugSAFE Mini, which is designed for daily use while at work or play, can fit easily into a pocketbook or jacket pocket, and comes with a 4 x daily pill tray system that allows medications to be pre-loaded each week. We are also working on a field –use Mobile Medical Station (MMS). The MMS is a waterproof, shockproof and secure rolling case with telescopic handle that is secured with our patented fingerprint technology. The MMS is designed to be used out in the field by mobile healthcare workers administering medications and general preventative care under the direction of the Affordable Healthcare Act’s Home Health initiative. The case is secured using our fingerprint interface and incorporates state of the art vital statistics monitoring equipment, a rugged field tablet containing patient H&P data which can be securely uploaded to the primary healthcare enterprise system and one of our Rx DrugSAFE fingerprint lockboxes for the safe and secure transportation of medications. The company is also working on a fingerprint padlock to be used to secure existing medical transport and equipment cases.
 

Professional Healthcare Products



Image result for Read This!  gif
 

RX Safes Inc. has (3) HUGE NYSE Partners!



McKesson Corp. $179 Billion Annual Sales @ $192.00 PPS on NYSE

Image result for McKesson Corp  gif


Cardinal Health @ $91 Billion Annual Sales @ $79.50 PPS on NYSE

Image result for Cardinal Health  gif



Amerisource Bergen with $80 Billion Annual Revs & $100 pps on NYSE **** Watch for a new DISTRIBUTION DEAL here shortly! ****



Image result for Amerisourcebergen gif


We plan to invest in the participation of their various marketing programs to provide exposure for our products within their channels of distribution, which are the national pharmacy chains as well as the many independently owned or franchised neighborhood pharmacies. We will also endeavor to build our traditional grass roots efforts, i.e., establishing our own demand at the end user level, in order to make these relationships a success. These distributors also provide products to commercial healthcare facilities, private practice doctors offices, nursing facilities, assisted living, rehabilitation centers, outpatient clinics and more.


 

RXSF Patent Protection and Intellectual Property Rights


Our patent protection provides us with a competitive advantage and a barrier to entry for our competitors within the consumer and commercial healthcare marketplaces, which are the primary target markets for our fingerprint technology and products. We have already successfully defended our patent rights and prevented competitors from entering these markets with other embedded fingerprint-based products and we will continue to aggressively protect our intellectual property rights as we build our patent portfolio.


 




We continue to identify new product opportunities for the implementation and licensing of our technology for commercial healthcare applications. We recently acquired rights to intellectual property to support the development of an innovative, biometrically controlled personal patient dosing device that will work with existing PCA (Patient Controlled Analgesia) manufactured pumps offered by Smiths Medical, Abbott Laboratories, and Hospira. This product is designed to prevent the administration of pain medications, such as morphine, by unauthorized family members, caregivers or clinicians, which can have serious and sometimes fatal effects on a patient.

 

RXSF Products Featured On "The Doctors" TV Show!


Image result for The Doctors TV Show gif


The Rx DrugSAFE was chosen out of several home drug security products to demonstrate how families can securely and safely store potentially dangerous prescription medications at home. https://www.youtube.com/watch?v=zH76WnhYp24

 

RX Safes, Inc. Daily Chart!

RX Safes, Inc. Weekly Chart!






Image result for check this out
 

Rx Safes Announces Retail Distribution Through CVS Health

New Rx DrugSAFE Now Available Online Through CVS.COM

October 20, 2015: 08:30 AM ET

http://money.cnn.com/news/newsfeeds/articles/marketwire/1223602.htm

Rx Safes, Inc. (OTC PINK: RXSF), the developer of autonomous fingerprint healthcare security products announced today that its flagship consumer product, the Rx DrugSAFE, is now part of CVS Health's national online offerings.

The new Rx DrugSAFE is now available at CVS.com. "The Rx DrugSAFE, the company's flagship consumer based product, has been the first choice of medical professionals for years because it's a real metal safe, secured by our autonomous fingerprint technology, so it only opens after it recognizes its authorized user," said Lorraine Yarde, CEO of Rx Safes, Inc. The National Community Pharmacists Association (NCPA) and Purdue Pharma, the leading manufacturer of Oxycontin pain medications, have used the Rx DrugSAFE in nationally released PSA's to demonstrate the need of locking up prescription drugs at home. CVS Health is now incorporating the new Rx DrugSAFE in its national online offering.

The new Rx DrugSAFE has gone through technology, structural and security updates that now include added levels of personal security to make sure drugs and medicines are securely locked up at home. As part of the new online offering by CVS Health, Rx Safes is making the Rx DrugSAFE more affordable for families by offering a manufacturers rebate program and special pricing through CVS Health.

"There is a real national epidemic of toddlers and teenagers accessing prescription drugs at home because parents do not lock up their medications. The medicine cabinet has become our nation's most dangerous drug dealer and a simple way to prevent a catastrophe for your family is to lock up your medications with an Rx DrugSAFE," noted Dr. Mary Ellen Renna, a nationally acclaimed pediatrician, Fox News medical commentator, author and company spokesperson. "This is why I have been working with Rx Safes to get the word out. As a pediatrician, I have seen far too many avoidable accidental poisoning and overdoses that could simply have been prevented by this product."

CVS Health is a great partner because it recognizes the Rx DrugSAFE as a real tool for families to fight against prescription drug misuse and abuse. With more than 7800 stores in North America and retail pharmacy sales exceeding $16.7 billion in 2014, CVS Health is one of the country's leading pharmacies. The CVS Health Pharmacists know their customers and play a very important role in their health care. The Rx DrugSAFE is now stocked and available and can be ordered directly at:

http://m.cvs.com/mt/www.cvs.com/shop/home-health-care/other-daily-living-aids/medicine-accessories/rx-drugsafe-personal-medication-lock-box-with-fingerprint-technology-skuid-242586#close

About 2500 kids a day experiment with prescription drugs for the first time, and 70% of them say they get these drugs from the home medicine cabinet. The prescription drug epidemic hits home hard and families suffer tremendously unnecessarily when simply locking up your medications could reduce drug abuse and drug addiction substantially. CVS Health and Rx Safes, Inc. would like you to join the fight by locking up your medications in a real safe, the Rx DrugSAFE. For more information on the Rx DrugSAFE, please visit us at www.rxdrugsafe.com, and to order your own Rx DrugSAFE, please visit CVS Health's online store at http://m.cvs.com/mt/www.cvs.com/shop/home-health-care/other-daily-living-aids/medicine-accessories/rx-drugsafe-personal-medication-lock-box-with-fingerprint-technology-skuid-242586#close.

This new online CVS Health offering of the Rx DrugSAFE is being established in advance of an in-store pilot program that will be announced shortly.

About Rx Safes, Inc.

Rx Safes is an emerging leader in the personal and professional healthcare drug security market. Our products incorporate proprietary patented fingerprint technology to provide drug security solutions for use in homes and healthcare facilities. Prescription drug misuse, skyrocketing insurance and pharmaceutical treatment costs and increased regulatory pressures create an unfortunate, yet necessary opportunity for Rx Safes to expand our reach and offerings in this growing market, valued at over $50 billion annually. Annual spending on healthcare technology products exceeds $34.5 billion. In addition, the market is being driven by ongoing Government support for successful drug abuse prevention initiatives, with a financial commitment of $25.4 billion in 2015 alone. For more information, please visit www.rxdrugsafe.com

Forward-Looking Statements for RXSF: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission.

Like us on Facebook at https://www.facebook.com/rx.drugsafe Follow us on Twitter at https://twitter.com/RxDrugSAFE





Image result for news animated gif



Image result for cvs pharmacy

RX Safes, Inc. Product Now Listed On The CVS Pharmacy Website!  See The Listing Herehttp://www.cvs.com/shop/home-health-care/other-daily-living-aids/medicine-accessories/rx-drugsafe-personal-medication-lock-box-with-fingerprint-technology-skuid-242586#close

 

 


Image result for news animated gif
 

RX Safes, Inc. has four (4) new filings out as of October 19, 2015!  You may review them here:



http://www.otcmarkets.com/stock/RXSF/filings



Image result for news animated gif

RX Safes Releases Shareholder Letter: Uplisting to NASDAQ!!!!!!


Outlines Future Growth Plans: NASDAQ BOUND!!!!!

http://www.otcmarkets.com/stock/RXSF/news

HENDERSON, NV -- (Marketwired) -- 10/12/15 -- Rx Safes, Inc. (OTC PINK: RXSF) the developer of autonomous fingerprint healthcare security products designed to combat drug abuse and diversion, today released a shareholder letter, outlining the Company's growth plans for the future.

Dear Valued Shareholder:

As your CEO, I understand the importance of communicating with you regularly and as such would like this letter to serve as an update on the efforts we have made over the last several months to reorganize the Company with an eye to attract more sophisticated institutional lending, as well as to eventually apply for listing on a national exchange such as the NASDAQ. The Company continues to demonstrate its ability to move the business forward, develop new products, build its IP portfolio and create new opportunities, all while facing continuing financial constraints. Our past experiences are serving us well in helping us put a plan of action in place to best overcome these types of challenges.

The OTC Markets provide a great platform for us to introduce the Company and its story to the investment community. However, recent shorting activity has negatively affected our stock price to the detriment of the Company and our shareholders as a whole. Over the last several months there appears to have been a concerted effort to put pressure on the Company's stock and it has been impossible for us to raise money from equity investors. This has forced the Company to seek interim funding through convertible debt financing, placing additional pressures on the balance sheet and making the company look financially weaker. Fortunately, through our rebranding initiative, we have begun to attract new shareholders who believe in our strategy and support the long-term vision for the Company. We recently paid off the remaining balance of a Convertible Note, which had partially converted. This was done to prevent further immediate dilution, which may have negatively impacted our stock. We have also taken steps to clear the balance of all outstanding convertible debt through the provision of a less dilutive $1,000,000 equity line. As of the date of this letter we have not completed the steps necessary to secure the equity line and as such, we may still be subject to one additional conversion before the end of the year and cannot control how this affects the market. However, we hope the steps we are taking will limit the pressure on the stock and will serve to increase shareholder equity.

The biggest change you may have seen recently is our new website which serves to re-brand and re-position the Company as we now focus our efforts on the lucrative professional healthcare marketplace. We intend to seek out and secure new distribution, manufacturing and sales relationships in the medical device and equipment marketplace. Based on the high profit margins attainable in this market, we hope this strategy will make the Company financially secure in the near future. In addition, the Board has been busy strategizing and outlining a plan for the Company to meet the requirements for listing on a national exchange such as the NASDAQ. We believe that the NASDAQ will offer a more friendly, professional, stable and welcoming market for our Company. While we currently do not meet the listing requirements for the NASDAQ exchange, we are now positioning the Company to start the process of meeting those requirements.

As part of the Company's goal to up-list, the Board and a Shareholder majority has approved a 200 for 1 reverse split of our common stock. You will have seen our pre-14c filing on Friday October 9, 2015 indicating this. Once approved, this means we will go from approximately 270,000,000 shares issued and outstanding to about 1,350,000 shares outstanding, with about 250,000 shares in the public float. The Board believes this is necessary step and in the best long-term interest of all of our shareholders, to weed out the game players and to improve our stock price so the Company can begin to meet the listing requirements for NASDAQ and create greater opportunity for our shareholders in the future. There could be some turbulence in the stock after the split and there will be those who will continue to criticize the Company and this move. However, as stated earlier, we feel the Company cannot raise equity capital outside of its supporting shareholders without such a move and we hope that the more seasoned shareholder will support our efforts and will help lift the Company over time.

As mentioned previously, this restructuring is necessary to make the Company more attractive to institutional lenders whose investment strategies include working with Companies to secure listing on the NASDAQ. The reverse split is our first step towards this. While we are moving through the administrative steps to facilitate the split, our Board has already begun developing and articulating a new business plan to attract seasoned investment bankers to assist the Company in raising equity capital as well as up-listing. This process will take time and is not guaranteed, but we believe with hard work and the right partners, it is extremely achievable. We have already begun speaking with several sophisticated Investment Banking firms with a focus in healthcare and the medical device space. These firms care more about the fundamentals of our business and understand the long-term value of our company, our technology and our products as they apply to an enormous underserved market suffering huge economic and social losses attributable to drug theft and diversion. While we have not yet entered into any agreements, we expect to announce a new investment banking relationship shortly.

We are committed to the success of this Company and are certain that the wait will be worthwhile for our supportive shareholders. We aim to prove that we are not the typical OTC Company and that a reverse split will makes us stronger as a Company not weaker.

In the meantime, it's business as usual!

We are presently in the process of re-energizing our efforts to secure sales for our newly enhanced Rx DrugSAFE product, having taken a 4-month hiatus to reposition and rebrand the Company and improve our core technology. We have re-engineered the product to incorporate an additional layer of security by adding an administrator, who is required to be present to authorize the enrollment of additional users. We have taken this step to demonstrate our continued commitment to the level of security offered by our products and as a stepping stone towards additional functionality we plan on integrating over the next several months to target the needs of the professional healthcare community.

We will be going live with a major retailer partner online and shortly thereafter will be announcing a pilot program for the Rx DrugSAFE product with this same partner, who is one of the largest national retail pharmacy chains. The program will be launched in 2 key strategic geographic markets initially, with the hopes that the results will warrant a national rollout in 2016.

We have recently identified several grants that could fit our community support model to help local community groups acquire Rx DrugSAFEs as part of educational and services based programs to combat drug abuse in certain communities. We will provide more information publicly as we get closer to those grant filing deadlines. With our new focus in this area, our Director, Dr. Susan Kutzner, will be heading our community-focused grant initiatives. Dr. Kutzner has over 25 years of government grant writing experience and will be instrumental in shaping this program for the Company.

On the professional healthcare side, the company will be filing for FDA 510K pre-market certification on 2 new products, the Rx SafeDOSE (PCA Pendant) and the Rx MyDOSE (Needleless Injection System). The SafeDOSE application will be filed this quarter and we are working on securing distribution relationships with leading manufacturers in the PCA market, in parallel with the FDA filing. Meanwhile, the Company is engaged in discussions with several major pharmaceutical companies to join in the FDA application for the MyDOSE product. The FDA requires that needleless injector certification be packaged along with a particular pharmaceutical formulary, and we are specifically targeting companies who offer controlled substances such as morphine, where security and authentication is of the utmost importance, in line with our overall business model of utilizing our fingerprint technology to improve the security of products which store and dispense controlled substances.

We are also in development of several other professional healthcare products designed for hospitals, healthcare facilities and EMS and as we move further along with those development projects, we will release news when appropriate and required. The integration of our autonomous fingerprint technology into various medical devices and products that store, dispense or regulate controlled substances is a game changer in healthcare. We are able to make these products more efficient and secure and the tighter controls our technology offers will reduce the unauthorized access to, and the diversion of, controlled substances.

We have revamped and have started to implement new sales initiatives in both the consumer and professional healthcare markets, but just like any new application of technology, establishing a footprint in these markets takes time and money, so we are busy securing the resources to do so. We are actively interviewing individuals to lead our sales efforts in all three industry categories, consumer, professional healthcare and government, and we will announce the appointment of these key personnel once secured. The company hopes to see initial results of these programs as early as the 1st quarter 2016.

The Company continues to work on expanding its offerings, but its progress, while blistering in some areas, is held back dramatically because of its current inability to attract real capital. In order to succeed with our product roadmap, the Company is taking the steps identified above to attract equity investment while positioning itself to move up to the NASDAQ exchange. We believe we have a great story to tell, led by an experienced management team who have a proven track record of partnering with the biggest names in industry and who have developed and sold autonomous biometric security products through some of the country's largest retailers. We are taking the successful aspects of that prior model, and have now focused all of our attention narrowly in the healthcare market that is suffering both financially as well as socially from theft, misuse and diversion of controlled medications.

Healthcare stakeholders are experiencing the negative impacts and are being held accountable and paying the price for the many issues caused by drug theft and diversion. Consequently, the industry is heavily investing in measures to address this drug diversion issue and we are presently the only company focusing 100% of our efforts to provide solutions in broad compliance of the Controlled Substance Abuse Act (CSA) which governs the handling of controlled substances and requires strict controls of the very same drugs which are the target for theft and diversion. This places us in a very strong position to take advantage of the investment being made in this area and to provide real solutions to address the issue.

The company continues to appreciate the strong support of its current shareholders, and we ask you to be patient as our strategy is designed for long-term growth and success. It is our goal to be the leader in the development of efficient and cost effective autonomous, fingerprint medical security solutions. Our objective is to positively impact what has become a national epidemic costing $484 billion dollars and 38,329 lives annually. To achieve this we will utilize our proprietary technology to develop medical devices, which integrate seamlessly into existing healthcare infrastructures, to improve the security of storage, transportation, monitoring and delivery systems for controlled substances. The Company's technology and products are positioned to prevent loss and reduce liability within the healthcare industry and to reduce the potential loss of life. We know the opportunity is there, we believe our products and technology can make a difference and we hope that our shareholders will see this also and support our long term plan to eventually leave the OTC Markets for a national exchange which we hope will deliver a greater return on investment for all.

Thank you for your continued support.

Lorraine Yarde, CEO

About Rx Safes, Inc.

Rx Safes is an emerging leader in the personal and professional healthcare drug security market. Our products incorporate proprietary autonomous fingerprint technology to provide drug security solutions for use in homes and healthcare facilities. Prescription drug misuse, skyrocketing insurance and pharmaceutical treatment costs and increased regulatory pressures create an unfortunate, yet necessary opportunity for Rx Safes to expand our reach and offerings in this growing market, valued at over $50 billion annually. Annual spending on healthcare technology products exceeds $34.5 billion. In addition, the market is being driven by ongoing Government support for successful drug abuse prevention initiatives, with a financial commitment of $25.4 billion in 2015 alone.

For more information, please visit www.rxdrugsafe.com

Forward-Looking Statements for RXSF:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission.

Like us on Facebook at https://www.facebook.com/rx.drugsafe
Follow us on Twitter at https://twitter.com/RxDrugSAFE

Investor Relations Contact:

Email: Email Contact
Telephone: 1-844-RXSAFES Ext 4

Source: Rx Safes, Inc.



Image result for news animated gif

 

Rx Safes Announces New Product Rights Acquisition


http://www.otcmarkets.com/stock/RXSF/news
 

MyDOSE Needleless Injector for Professional Healthcare

 

HENDERSON, NV -- (Marketwired) -- 10/06/15 -- Rx Safes, Inc. (OTC PINK: RXSF), the developer of autonomous fingerprint healthcare security products designed to combat drug abuse and diversion, announced today that it has formed a partnership with MIKA MEDICAL and MK GLOBAL, a leading Korean innovative medical device and distribution company, to exclusively distribute their proprietary, reusable needleless injection system in the US market. The agreement calls for Rx Safes to further develop the product by integrating its autonomous fingerprint interface into the device, allowing only authorized patients and healthcare workers the ability to administer controlled substances including serious pain medications, through painless injection. Rx Safes will own all of the new intellectual property rights developed as part of this initiative and MIKA, which is an ISO:13485 certified manufacturer, will manufacture the new fingerprint activated needleless device for Rx Safes.

"The MyDOSE product is a reusable needleless injection system that will feature the company's autonomous fingerprint technology, so only authorized patients and caregivers can inject medication for pain, once authenticated by the device. This is another innovative application of our company's technology into an existing medical device, and is consistent with our company mission to secure the storage and dispensing of potentially dangerous medications," noted Lorraine Yarde, CEO at Rx Safes, Inc.

The Injectable Drug Delivery Market exceeds $326 billion presently and is expected to grow to $574 billion by 2020. Through this new partnership, Rx Safes will be developing the world's first fingerprint activated needleless injection system, and will be well positioned to capture its share of this growing market. Needleless injection systems have been slowly gaining traction and the FDA has approved certification of these devices in the areas of flu vaccinations and insulin administration because they are designed to deliver medications efficiently and pain-free, without breaking or puncturing the skin. "There is a real need to ensure individuals are actually authorized to inject controlled medications as part of a pain management program whether recuperating from surgery or otherwise treating withdrawals from addiction," noted Rx Safes' Board Member, Dr. Susan Kutzner. "The company believes that this product will revolutionize pain free administration of controlled medications and will be adopted quickly by the healthcare community," Dr. Kutzner added.

To date the FDA has required needleless injection systems be paired with a pharmaceutical formulary in order to be awarded FDA 510K certification. The company has started discussions with a high profile pharmaceutical company that concentrates on manufacturing pain medications. The company expects to file for certification with the FDA for this product once that relationship is finalized, possibly as soon as early next quarter.

About Rx Safes, Inc.

Rx Safes is an emerging leader in the personal and professional healthcare drug security market. Our products incorporate proprietary autonomous fingerprint technology to provide drug security solutions for use in homes and healthcare facilities. Prescription drug misuse, skyrocketing insurance and pharmaceutical treatment costs and increased regulatory pressures create an unfortunate, yet necessary opportunity for Rx Safes to expand our reach and offerings in this growing market, valued at over $50 billion annually. Annual spending on healthcare technology products exceeds $34.5 billion. In addition, the market is being driven by ongoing Government support for successful drug abuse prevention initiatives, with a financial commitment of $25.4 billion in 2015 alone.

For more information, please visit www.rxsafes.com.

Forward-Looking Statements for RXSF:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission.

Investor Relations Contact:
Rx Safes, Inc.
Email: Email Contact
Telephone: 1-844-RXSAFES Ext 4

Like us on Facebook at https://www.facebook.com/rx.drugsafe
Follow us on Twitter at https://twitter.com/RxDrugSAFE



Image result for news animated gif


The Medical Cannabis Institute


Image result for cannabis


On March 26, 2015, we announced that we have established our first marijuana business reseller agreement with Medical Cannabis Institute (MCI), a leading resource for cannabis education, information and training, located in Las Vegas, Nevada. MCI assists patients in navigating the complex world of medical marijuana and will be offering the Rx DrugSAFE for sale to its clients, within its high traffic facility as well as at its website. 23 states plus DC have legalized the sale of marijuana products for medical purposes and the market is growing faster than any other emerging industry. This presents a unique opportunity for Rx Safes to position its Rx DrugSAFE product as a tool to keep marijuana and cannabis infused edibles securely locked up and away from children in the home

Image result for things to remember clipart
 

Our key focus is to sell and distribute our products and technology through the development of business relationships with strategic partners who have a stake in our industry and have existing channels to market, or an audience for our products both in the consumer and commercial healthcare space. We are presently in discussions with a major retail pharmacy that is developing a national campaign to create awareness, and provide tools, to prevent prescription drug abuse.

 

We are also presently in discussions with a major academic establishment with a view to collaborating on research efforts incorporating the Rx DrugSAFE, which will be given to at risk families. The study would track the use and effectiveness of the Rx DrugSAFE in preventing access to dangerous narcotics and in turn preventing the potential injury caused by the use of these drugs by unauthorized persons. This collaboration may also include the co-development of a new product offering incorporating our patented fingerprint interface into a product concept developed by the facilities mechanical engineering group.

 

We are working on a program for a major sports league brand where our products will be incorporated into a campaign sponsored by the entity to increase awareness on the dangers of prescription drugs and the importance of securing them in the home environment.

 

Image result for Listen to this



HUGE INTERVIEW KRIS TOLLEY SHOW >> (AUDIO)Rx Safes, OBN, Kris, Tolley Radio Interview >> When a child steals prescription drugs from the medicine cabinet of an unsuspecting family member, this can quickly lead to addiction, often with deadly results. Every household should lock up their medications with the Rx DrugSAFE fingerprint medicine lockbox. Preventing access prevents abuse! Josh Tolley interviews Lorraine Yarde, CEO, Rx Safes, Inc., Director Darrell Weaver from the Oklahoma Bureau of Narcotics and a young man battling addiction who bravely comes forward to tell his story.  

https://www.youtube.com/watch?v=bPPk4eMqGaE

 

FORM 8-K filed on March 7, 2016:  Click Here

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GNID
Current Price
Volume:
Bid Ask Day's Range
SureTrader
PostSubject
#28448  Sticky Note Reg Sho shorts are the toxics!!! Toxic Avenger 09/27/16 07:18:28 AM
#27657  Sticky Note GNID - Daily and Weekly Chart The_Free_Nebula 09/23/16 07:17:24 PM
#27550  Sticky Note $GNID **Easy Money, Must Read** Guaranteed Nasdaq Up Cheeky 09/23/16 02:48:50 PM
#26086  Sticky Note GNID will hit $4 on the second Tuesday.of.next.week. waterchaser 08/05/16 08:59:33 AM
#28767   8k is needed if we had acquisitions. Not KING T 09/27/16 09:18:01 PM
#28766   I don't think an 8k is needed for KING T 09/27/16 09:15:27 PM
#28764   80% Fri, 170% Tue, 54% today! Continues tomorrow. Garyst 09/27/16 08:46:06 PM
#28759   Yes and it's not pretty! Orwell99 09/27/16 08:18:41 PM
#28758   No BC a lot of people here constantly TradeALLday 09/27/16 08:18:36 PM
#28757   Charts are worthless in this cesspool. GNID moves waterchaser 09/27/16 08:17:08 PM
#28756   You have seen the filings yourself!!!GNID $trato$phere 09/27/16 08:15:28 PM
#28755   This is said over and over but the TradeALLday 09/27/16 08:14:17 PM
#28754   I call it smoke and mirrors.GNID is an waterchaser 09/27/16 08:12:34 PM
#28753   Stop playing your mind games POS! $trato$phere 09/27/16 08:11:16 PM
#28752   Ok...a bid close in the high teens by The_Free_Nebula 09/27/16 08:09:21 PM
#28750   That's obviously on top of some profit taking. bigcut 09/27/16 08:02:06 PM
#28748   I'm back Cheeky and seeing GREEN GREEN and bigcut 09/27/16 07:58:02 PM
#28747   Lmao, millions on the bid. Unreal tales taking Cheeky 09/27/16 07:56:27 PM
#28746   Retail are the only ones trading GNID. Toxic Cheeky 09/27/16 07:51:00 PM
#28745   LMAO! GNID Over .20 tomorrow! $trato$phere 09/27/16 07:49:44 PM
#28744   It's definitely being run. Can retail make money Toxic Avenger 09/27/16 07:27:32 PM
#28743   Can this pos with its ratty toxic leaning The_Free_Nebula 09/27/16 07:19:11 PM
#28742   Ok The_Free_Nebula 09/27/16 07:11:42 PM
#28741   Yet it keeps going up!!!! $trato$phere 09/27/16 07:11:11 PM
#28740   Suicide buy.... The_Free_Nebula 09/27/16 07:06:27 PM
#28738   Sep 27 Volume 353,475 - Short Volume 157,267 - % malagueule 09/27/16 06:57:31 PM
#28737   The pie in the sky still has to The_Free_Nebula 09/27/16 06:54:26 PM
#28736   My goals are long term, don't give a Cheeky 09/27/16 06:51:27 PM
#28735   Here's the Truth then....GNID & Wellington Shield's signed Cheeky 09/27/16 06:49:18 PM
#28734   Let's see it hold the teens this week 1st The_Free_Nebula 09/27/16 06:48:47 PM
#28733   Suicide buys? GNID is Up listing to the Cheeky 09/27/16 06:46:21 PM
#28732   LMAO!!!!!!!! $trato$phere 09/27/16 06:42:49 PM
#28731   Horse chit ...real good experienced traders are not The_Free_Nebula 09/27/16 06:37:41 PM
#28730   Most should have added when the suicide buys The_Free_Nebula 09/27/16 06:34:38 PM
#28729   Added at .11 Falcon5150 09/27/16 06:30:38 PM
#28728   I added as well from the .11s and viper666 09/27/16 06:09:34 PM
#28727   Last 6 Days History retiredtech 09/27/16 05:52:10 PM
#28726   blue sky to 0.5+ and beyond MONEY_MONEY 09/27/16 05:38:43 PM
#28725   Good experienced traders expected some profit taking today. $trato$phere 09/27/16 05:34:32 PM
#28724   Yeah I added at around .08. Ill probably ajayman 09/27/16 05:16:04 PM
#28723   A lot of people loaded then.. But then TradeALLday 09/27/16 05:13:13 PM
#28722   I really regret not getting more when it ajayman 09/27/16 05:09:19 PM
#28721   Only gonna get better!!! GNID $trato$phere 09/27/16 04:30:48 PM
#28720   Daily Chart looks Amazing >>> investorshub.advfn.com/uimage/uploads/2016/ Cheeky 09/27/16 04:25:09 PM
#28718   Hmm, broke and held the 50ma @.1181. I Cheeky 09/27/16 04:22:26 PM
#28717   Yep $7,000 and $10,000 buys are childs play!! $trato$phere 09/27/16 04:20:56 PM
#28716   Including a $7000-$10k buy, but that's not bullish Cheeky 09/27/16 04:12:10 PM
#28715   Most of the paints were some of those prospector777x3 09/27/16 04:10:55 PM
#28714   It was green before that! $trato$phere 09/27/16 04:10:08 PM
#28713   Green regardless of Paint. Still raining unreal I see. Cheeky 09/27/16 04:08:49 PM
#28712   I love that color!! $trato$phere 09/27/16 04:07:12 PM
#28711   Great day no matter what. Green is green. cheapdude123 09/27/16 04:06:40 PM
#28710   Painted The_Free_Nebula 09/27/16 04:04:26 PM
#28709   Lmao, +54%, BULLS WON. Geez, it's GREEN. Cheeky 09/27/16 04:03:40 PM
PostSubject